Fig. 2

TNBC is sensitive to lipid-specific oxidative stress in vitro. (A, B) Immunoblot analysis of metM-Wnt^lung, E0771 and M-Wnt cells probed for Nrf2 (A), GPX4 (B) and ß-actin after treatment with erastin for 24 h (A: n = 4/group, B: n = 5/group). (C) mRNA expression of SLC7A11 in metM-Wnt^lung, E0771 and M-Wnt cells with erastin treatment for 24 h (n = 5/group). (D-F) Percent survival of metM-Wnt^lung (D), M-Wnt (E) and E0771 (F) cells treated with 5µM erastin or 0.5µM RSL3 combined with 500µM N-acetyl cysteine (NAC) for 24 h, relative to a DMSO-treated control for each cell line (n = 3/group). (G-I) Percent survival of metM-Wnt^lung (G), M-Wnt (H) and E0771 (I) cells treated with 5µM erastin or 0.5µM RSL3 combined with 5µM ferrostatin-1 or 5µM liproxstatin-1 for 24 h, relative to a DMSO-treated control for each cell line (n = 3–4/group). (J, K) Percent survival of metM-Wnt^lung, M-Wnt and E0771 cells treated with erastin (J) or RSL3 (K) for 24 h. (n = 6/group). Statistical significance determined by Kruskal-Wallis test with Dunn’s multiple comparison test (A); one-sample t test (B, C); or two-way ANOVA (D-I) with Tukey’s multiple comparison test (D-F, K), Šídák’s multiple comparison test (J), or Dunnett’s multiple comparison test (G-I) (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)